Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004822 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01004822 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 31 participants.
The verdict
NCT01004822, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.
Interventions
- DRUG CVX-241
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2010-03 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01004822
The ClinicalTrials.gov registry entry for NCT01004822 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CVX-241 is the first listed.
NCT01004822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01004822 about?
NCT01004822 is a clinical study titled "A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors". The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.
What is the current status of trial NCT01004822?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2010-03. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01004822?
The interventions under investigation include: CVX-241 (DRUG).
Who is sponsoring clinical trial NCT01004822?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.